Clinical Trials Logo

Systemic Lupus Erythematosus clinical trials

View clinical trials related to Systemic Lupus Erythematosus.

Filter by:
  • Not yet recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06429800 Not yet recruiting - Clinical trials for Systemic Lupus Erythematosus

A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Lupus Nephritis

Start date: October 31, 2024
Phase: Phase 1
Study type: Interventional

The purpose of the study is to evaluate the safety and preliminary efficacy of ATA3219 (following lymphodepletion) for treatment of participants with lupus nephritis (LN).

NCT ID: NCT06421701 Not yet recruiting - Clinical trials for Systemic Lupus Erythematosus

Anti-CD19 CAR-NK Cells in Refractory/Relapsed Systemic Lupus Erythematosus

Start date: June 1, 2024
Phase: Phase 1
Study type: Interventional

This study is a single-center, open-label, single-arm, dose-escalation trial. The aim of this study is to investigate the safety and efficacy of anti-CD19 CAR-NK cells in patients with refractory/relapsed systemic lupus erythematosus.

NCT ID: NCT06417398 Not yet recruiting - Clinical trials for Rheumatoid Arthritis

Preliminary Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases

Start date: May 14, 2024
Phase: Early Phase 1
Study type: Interventional

To evaluate the safety of UTAA09 injection in the treatment of relapsed/refractory (R/R) autoimmune disease (AID). To evaluate the pharmacokinetic (PK) profile of UTAA09 injection in patients with R/R AID. To evaluate the pharmacodynamic (PD) characteristics of UTAA09 injection in patients with R/R AID. To evaluate the initial efficacy of UTAA09 injection in the treatment of R/R AID subjects. To evaluate the immunogenicity of UTAA09 injection in R/R AID subjects.

NCT ID: NCT06413511 Not yet recruiting - Clinical trials for Systemic Lupus Erythematosus

A Study to Investigate the Safety and Pharmacological Effect of a Single Intravenous Infusion of Belantamab in Male and Female Participants Aged 18 to 75 With Moderate to Severe Systemic Lupus Erythematosus

Start date: May 29, 2024
Phase: Phase 1
Study type: Interventional

The goal of this clinical trial is to assess the safety and tolerability profile of belantamab. The study will also assess how the levels of belantamab change over time and body's reaction to it in participants with moderate to severe systemic lupus erythematosus (SLE).

NCT ID: NCT06411639 Not yet recruiting - Clinical trials for Systemic Lupus Erythematosus

Pharmacokinetics Study of Ianalumab in Chinese Participants With Autoimmune Diseases

Start date: November 25, 2024
Phase: Phase 1
Study type: Interventional

The purpose of this pharmacokinetic (PK) study is to describe the PK profile of ianalumab following s.c. administration in Chinese participants with systemic lupus erythematosus (SLE) and/or Sjögren's disease (SjD). Collection of intensive PK data from Chinese population had been designed in the ianalumab Phase 3 studies of SjD CVAY736A2302 (NCT05349214) and lupus nephritis (LN) CVAY736K12301 (NCT05126277) on an optional basis. This study is conducted to provide supplementary Chinese PK data in addition to the intensive PK data from the two Phase 3 studies .

NCT ID: NCT06411249 Not yet recruiting - Clinical trials for Systemic Lupus Erythematosus

A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)

BE-EARLY
Start date: June 4, 2024
Phase: Phase 4
Study type: Interventional

This is a prospective, open-label, single arm 3-year clinical study to describe the short-term and long-term efficacy and safety of belimumab in participants with autoantibody positive early SLE with ongoing disease activity despite stable initial SLE therapy.

NCT ID: NCT06404723 Not yet recruiting - Clinical trials for Systemic Lupus Erythematosus

The Predictive and Prognostic Values of the Fibrinogen to Albumin Ratio and C-reactive Protien to Albumin Ratio in Systemic Lupus Erythematosus Patients

Start date: June 1, 2024
Phase:
Study type: Observational

The aim of the study was to study the predictive value of FAR and CAR in order to provide a new predictive biomarkers for the disease activity and prognosis.

NCT ID: NCT06400537 Not yet recruiting - Clinical trials for Systemic Lupus Erythematosus

Clinical Study of A-319 in the Treatment of Active/Refractory Systemic Lupus Erythematosus

Start date: May 2024
Phase: Phase 1
Study type: Interventional

The purpose of the study is to explore the safety and efficacy of recombinant CD19xCD3 double antibody (A-319) in active/refractory systemic lupus erythematosus (SLE).

NCT ID: NCT06394063 Not yet recruiting - Clinical trials for Systemic Lupus Erythematosus

Efficacy and Safety of Telitacicept for Prevention of Flares in SLE Patients

Start date: June 30, 2024
Phase: N/A
Study type: Interventional

This study is a randomized, double-blind, placebo-controlled single-center clinical trial. The aim of this study is to investigate the efficacy and safety of low-dose telitacicept for prevention of flares in SLE patients with low disease activity.

NCT ID: NCT06379646 Not yet recruiting - Clinical trials for Systemic Lupus Erythematosus

An Clinical Study of YTS109 Cell Injection in Subjects With Recurrent/Refractory Autoimmune Disease

Start date: April 22, 2024
Phase: N/A
Study type: Interventional

An exploratory clinical study of the safety and efficacy of YTS109 cell injection in subjects with recurrent/refractory autoimmune disease